The task force consists of 16 experts in disease prevention and evidence-based medicine who periodically conduct screening tests and evaluate preventive treatment. Members are appointed by the director of the Federal Agency for Healthcare Research and Quality, but the group is independent and its recommendations often help shape U.S. medical practice.
The guidelines, which are not yet finalized, are likely to affect millions of adults at high risk for heart disease, which continues to be the leading cause of death in the United States, even at cowardly age. The panel will receive public comments on its recommendations until November and its draft guidelines are usually adopted a few days later.
Two years ago, the American College of Cardiology and the American Heart Association jointly narrowed down their recommendations to say that aspirin should be highly preferred for people in their 40s and 70s who have never had a heart attack or stroke. In aspirin, companies say “usually not, sometimes yes” for initial resistance. This suggestion differs from the Taskforce’s new draft guidelines for a cutoff at age 60.
“When we looked at the literature, most of it suggested that net balance was not favorable for most people – there was more bleeding than heart attack prevention,” said Dr. A.S. Amit Khera said. “And it’s not bleeding through the nose, it could be bleeding into the brain.”
And long before 2014, a Food and Drug Administration review concluded that aspirin should not be used for early prevention, such as protection from the first heart attack or stroke and to look at the risks.
The task force, which previously made a universal recommendation for high-risk adults to take baby aspirin in their 50s, if they are less likely to have side effects, now suggests that high-risk adults in their 40s and 50s should talk to their doctors and Will make a personal decision about whether to start a daily life. (According to the American College of Cardiology / American Heart Association Calculator, to estimate risk, the panel defined “high risk” as anyone who has a 10 percent or more risk of cardiovascular event in the next 10 years.)
In 2001, when the task force issued its final recommendations supporting the widespread use of aspirin for early prevention for high-risk individuals and saying that the benefits outweighed the risks, some critics said the panel was wrong. The chair of cardiology at the Cleveland Clinic, Dr. Steven Nissen then said he was concerned that the use of aspirin would do more harm than good. Gastroenterologists said they feared that patients taking aspirin would avoid their colon cancer screening.